7 active not recruiting, 4 completed, 1 terminated, 1 withdrawn. 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Active not recruiting 7, Completed 4, Terminated 1, Withdrawn 1 |
Follow Poorly Differentiated Thyroid Gland Carcinoma: new trials by email Literature Review of Poorly Differentiated Thyroid Gland Carcinoma trials Research Report on Poorly Differentiated Thyroid Gland Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer Lenvatinib, Pembrolizumab - Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2021-11-04 | 2026-08-10 |
| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib - Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2021-02-26 | 2026-11-10 |
| Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer Lenvatinib, Pembrolizumab, Chemotherapy - Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Withdrawn | Saint Petersburg State University, Russia | 2020-12-28 | 2024-03-25 | |
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Trametinib, Dabrafenib, PDR001 - Thyroid Cancer, Thyroid Cancer, Follicular | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 19 | 2020-09-02 | 2026-09-17 |
| Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 11 | 2020-02-10 | 2026-11-13 |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Lenvatinib, Sorafenib, Cabozantinib - Thyroid Cancer, Thyroid Cancer, Medullary | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 6 | 2018-08-06 | 2021-07-14 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2018-04-27 | 2026-11-10 |
| Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) Laboratory Biomarker Analysis, Lenvatinib, Lenvatinib Mesylate - Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma | Phase 2 | Completed | Academic and Community Cancer Research United | 57 | 2018-02-07 | 2025-08-29 |
| Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer Atezolizumab, Bevacizumab, Cobimetinib - Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 50 | 2017-07-27 | 2026-07-24 |
| Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Iodine I-131, Placebo Administration, Selumetinib - Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Completed | Academic and Community Cancer Research United | 60 | 2015-05-04 | 2024-07-26 |
| Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Computed Tomography, Iodine I 124, Iodine I-131 - Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 34 | 2014-08-14 | 2026-11-13 |
| Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Cabozantinib S-malate, Laboratory Biomarker Analysis - Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 25 | 2013-05-08 | 2018-04-03 |
| Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fludeoxyglucose F-18, Laboratory Biomarker Analysis - Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 57 | 2004-10-25 | 2026-11-12 |
Thyroid Neoplasms (11) · Thyroid Cancer, Papillary (9) · Adenocarcinoma, Follicular (8) · Thyroid Carcinoma, Anaplastic (5) · Thyroid cancer, Hurthle cell (3) · Carcinoma, Medullary (2) · Adenoma, Oxyphilic (1) · Bone Neoplasms (1) · Giant Cell Tumor of Bone (1) · Histiocytoma, Malignant Fibrous (1) · Osteosarcoma (1) · Ovarian Neoplasms (1) · Sarcoma (1) · Thyroid Diseases (1) · Thyroid cancer, follicular (1)
Endocrine Gland Neoplasms (13) · Endocrine System Diseases (13) · Neoplasms (13) · Neoplasms by Site (13) · Carcinoma (12) · Head and Neck Neoplasms (12) · Neoplasms by Histologic Type (12) · Neoplasms, Glandular and Epithelial (12) · Thyroid Diseases (11) · Adenocarcinoma (9) · Adenocarcinoma, Papillary (9) · Carcinoma, Neuroendocrine (2) · Neoplasms, Ductal, Lobular, and Medullary (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2)
lenvatinib (4) · Magnetic Resonance Spectroscopy (3) · pembrolizumab (3) · CTLA-4 Antigen (2) · Iodine-131 (2) · Ipilimumab (2) · Nivolumab (2) · Sorafenib (2) · cabozantinib (2) · trametinib (2) · 130-nm albumin-bound paclitaxel (1) · AZD 6244 (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Cyclophosphamide (1)
M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (4) · Academic and Community Cancer Research United (2) · H. Lee Moffitt Cancer Center and Research Institute (1) · Memorial Sloan Kettering Cancer Center (1) · Saint Petersburg State University, Russia (1)
United States (12) · Russia (1)
Alan L Ho (2) · Maria E Cabanillas (2) · Alan L Ho, MD, PhD (1) · Amir A Jazaeri (1) · Bhavana Konda (1) · Bryan R Haugen (1) · Christine H. Chung, M.D. (1) · Manisha H Shah (1) · Manisha Shah (1) · Mark Zafereo (1) · Yuliya Mikheeva, M.D., Ph.D. (1)
PMID 33720068, PMID 28817373, PMID 39133806, PMID 39446377, PMID 42673705
P30CA015083 (2), P30CA016058 (2), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM62206 (1), N01CM62207 (1), P30CA008748 (1), P50CA172012 (1), R01CA184724 (1), U01CA076576 (1), UM1CA186705 (1), UM1CA186712 (1)